Ionis Pharmaceuticals Inc
Company Profile
Business description
Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and partner Biogen brought Spinraza to market in 2016 as a treatment for a rare neuromuscular disorder, spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019). Ionis and AstraZeneca launched polyneuropathy drug Wainua in 2024.
Contact
2855 Gazelle Court
CarlsbadCA92010
USAT: +1 760 931-9200
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2024
Employees
927
Ionis Pharmaceuticals Inc News & Analysis
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
---|---|---|---|
All Ordinaries | 8,316.70 | 98.30 | -1.17% |
CAC 40 | 7,274.48 | 19.89 | -0.27% |
DAX 40 | 19,884.75 | 85.11 | -0.43% |
Dow JONES (US) | 42,840.26 | 498.02 | 1.18% |
FTSE 100 | 8,084.61 | 20.71 | -0.26% |
HKSE | 19,720.70 | 31.81 | -0.16% |
NASDAQ | 19,572.60 | 199.83 | 1.03% |
Nikkei 225 | 38,701.90 | 111.68 | -0.29% |
NZX 50 Index | 12,878.58 | 25.53 | -0.20% |
S&P 500 | 5,930.85 | 63.77 | 1.09% |
S&P/ASX 200 | 8,067.00 | 101.20 | -1.24% |
SSE Composite Index | 3,368.07 | 1.96 | -0.06% |